Claims for Patent: 9,351,940

Summary for Patent: 9,351,940

Title:	Nanoparticles comprising esters of poly (methyl vinyl ether-co-maleic anhydride) and uses thereof
Abstract:	The present invention relates to nanoparticles for encapsulating compounds, the preparation and uses thereof, said nanoparticles being based on half (C.sub.1-C.sub.4) alkyl esters of poly (methyl vinyl ether-co-maleic anhydride) (PVM/MA) copolymers. Said nanoparticles can encapsulate or incorporate a product of interest for use in the agricultural, cosmetic, food or pharmaceutical fields.
Inventor(s):	Salman; Hesham H. A. (Noain-Navarra, ES), Goni Azcarate; Izaskun (Pamplona, ES)
Assignee:	BIONANOPLUS, S.L. (Noain-Navarra, ES)
Application Number:	14/111,855
Patent Claims:	1. A nanoparticle selected from the group consisting of: a) a matrix nanosphere, wherein said matrix nanosphere comprises a matrix, said matrix comprising a half (C.sub.1-C.sub.4) alkyl ester of a poly (methyl vinyl ether-co-maleic anhydride) (PVM/MA) copolymer; and b) a core-shell vesicular nanocapsule, wherein said core-shell vesicular nanocapsule comprises a core and a shell, said shell comprising a half (C.sub.1-C.sub.4) alkyl ester of a PVM/MA copolymer, wherein the nanoparticle has long-term stability in aqueous media. 2. The nanoparticle according to claim 1, wherein (C.sub.1-C.sub.4) alkyl is ethyl, isopropyl or n-butyl. 3. The nanoparticle according to claim 1, wherein the average size of the nanoparticle is comprised between 50 and 300 nm. 4. The nanoparticle according to claim 1, further comprising a product of interest. 5. A composition comprising at least one nanoparticle according to claim 1, and a carrier. 6. The nanoparticle according to claim 5, wherein said nanoparticle comprises a product of interest. 7. The nanoparticle according to claim 6, wherein said product of interest is an herbicide, an insecticide, a fungicide, an anti-aging product, an anti-acne product, a facial care product, a pigmented cosmetic, a cosmetical, a personal care product, a product for sunscreen/suncare, a product for tooth-cleaners, toothpastes, or rinses, a product for shampoos, a perfume, a hair products, folic acid, 4-aminobenzoic acid, niacin or vitamin B3, pantothenic acid or vitamin B5, thiamine monophosphate, thiamine pyrophosphate, thiamine triphosphate, ascorbic acid, pteroylpolyglutamic acids, folinic acid, nicotinic acid, hyaluronic acid, thioctic acid, p-coumaric acid, caffeic acid, a vitamin of the A, D, E, K families and derivatives thereof, a phospholipid, a carotenoid, a fatty acid, an omega-3 fatty acid, an amino acid, a phytostanol, a phytosterol, a polyphenol, an analgesic agent, an antialopecia agent, an antianginal agent, an antibacterial agent, an antidepressant agent, an antifungal agent, an antihypertensive agent, an antiinflammatory agent, an antineoplastic agent, an antipyretic agent, an antipsychotic agent, an anxiolytic agent, a bronchodilator agent, a glucocorticoid, an immunosuppressant agent, or any combination thereof. 8. A composition comprising: a) a component selected from the group consisting of: i) at least one nanoparticle according to claim 1 further comprising a product of interest; and ii) a solution or suspension containing a half (C.sub.1-C.sub.4) alkyl ester of a poly (methyl vinyl ether-co-maleic anhydride) (PVM/MA) copolymer and a product of interest in a medium, said medium comprising a volatile water miscible alcohol and an aqueous medium, wherein the amount of aqueous medium is lower than the necessary amount of aqueous medium to form nanoparticles; and b) a carrier, wherein said product of interest is selected from the group consisting of acetylsalicylic acid, alpha-atrial natriuretic peptide, arginine vasopressin, atropine, augmerosen, atorvastatin, bevacizumab, calcitonins, chorionic gonadotropins, corticotropin, desmopressin, epibatidine, cetuximab, exenatide, trastuzumab, adalimumab, human insulin, ketoconazole, lanreotide, lutropin alpha, metoprolol, minoxidil, nesiritide, octreotide, paclitaxel, paracetamol, pegaptanib, recombinant follicle stimulating hormone, recombinant growth factors, infliximab, rituximab, sermorelin, somatotropin, a taxane derivative, taxol, teriparatide acetate, thyrotropin, triclosan, urofollitropin, omalizumab, actinomycin D, albendazole, aldosterone, alprazolam, amiodarone, amitriptyline, amprenavir, asimadoline, atorvastatin, bunitrolol, buspirone, camptothecin, carbamazepine, carvedilol, celiprolol, cyclosporine A, cimetidine, clotrimazole, colchicine, cortisone, daunorubicin, debrisoquine, dexamethasone, diazepam, digitoxin, digoxin, diltiazem, docetaxel, domperidone, doxorubicin, efavirenz, epirubicin, erythromycin, ergotamine, estradiol, estradiol glucuronide, erlotinib, etoposide, phenytoin, fentanyl, felodipine, phenothiazines, fexofenadine, fluoroquinolones, fluorouracil, FK-506, gentamicin, griseofulvin, hydrocortisone, imatinib, indinavir, itraconazole, ivermectin, ketoconazole, kaempferol, levofloxacin, lidocaine, loperamide, losartan, lovastatin, mebendazole, methylprednisolone, methotrexate, mibefradil, midazolam, nisoldipine, morphine, nelfinavir, nicardipine, nitrendipine, nifedipine, ondansetron, paclitaxel, pentazocine, praziquantel, prednisolone, prednisone, quercetin, quinidine, ranitidine, rapamycin, rifabutin, rifampicin, ritonavir, saquinavir, sirolimus, sulfamethizole, tacrolimus, tamoxifen, talinolol, teniposide, terfenadine, tetracycline, topotecan, triamcinolone, valspodar, verapamil, vinblastine, vincristine, vindesine, zopiclone, and mixtures thereof. 9. The nanoparticle according to claim 5, wherein said composition is in the form of a dry powder. 10. The nanoparticle according to claim 5, wherein said carrier comprises a pharmaceutically acceptable excipient for the administration thereof by the buccal, dental, nasal, ocular, oral, parenteral, rectal, topical, or vaginal routes, or a cosmetically acceptable excipient for the administration thereof by topical route. 11. A foodstuff comprising a nanoparticle according to claim 1. 12. A method of treatment of hair loss in a subject comprising the administration to said subject of a nanoparticle according to claim 4 loaded with minoxidil. 13. A method of treatment of a buccal infection in a subject comprising the administration to said subject of a nanoparticle according to claim 4 loaded with triclosan or ketoconazole. 14. A process for producing the matrix nanosphere of claim 1, wherein the matrix nanosphere comprises a matrix, said matrix comprising a half (C.sub.1-C.sub.4) alkyl ester of a poly (methyl vinyl ether-co-maleic anhydride) (PVM/MA) copolymer, said process comprising contacting an organic solution or suspension containing a half (C.sub.1-C.sub.4) alkyl ester of a PVM/MA copolymer with an aqueous medium in order to form said matrix nanosphere. 15. A process for producing the matrix nanosphere of claim 1, wherein the matrix nanosphere comprises a product of interest, wherein said matrix nanosphere comprises a matrix, said matrix comprising a half (C.sub.1-C.sub.4) alkyl ester of a poly (methyl vinyl ether-co-maleic anhydride) (PVM/MA) copolymer, said process comprising: a) contacting an alcoholic or hydroalcoholic solution or suspension comprising said product of interest and said half (C.sub.1-C.sub.4) alkyl ester of the PVM/MA copolymer with an aqueous medium; or, alternatively, b) contacting an alcoholic solution or suspension comprising said product of interest and said half (C.sub.1-C.sub.4) alkyl ester of the PVM/MA copolymer with an aqueous medium; or, alternatively, c) contacting an organic solution or suspension comprising said product of interest and said half (C.sub.1-C.sub.4) alkyl ester of the PVM/MA copolymer with an aqueous medium, wherein said organic solution or suspension comprises a non-volatile water miscible solvent. 16. A process for producing the core-shell vesicular nanocapsule of claim 1, wherein the core-shell vesicular nanocapsule comprises a product of interest, wherein said core-shell vesicular nanocapsule comprises a core and a shell, said shell comprising a half (C.sub.1-C.sub.4) alkyl ester of a PVM/MA copolymer, said process comprising contacting a solution or suspension comprising said product of interest and said half (C.sub.1-C.sub.4) alkyl ester of a PVM/MA copolymer with an aqueous medium. 17. A process for producing a nanoparticle of claim 1, said process comprising removing a solvent in an hydroalcoholic solution or suspension containing a half (C.sub.1-C.sub.4) alkyl ester of a PVM/MA copolymer and a water miscible alcohol, wherein the amount of water is lower than the necessary amount of water to form the nanoparticles. 18. The process according to claim 17 further comprising a product of interest. 19. An in situ process for producing a nanoparticle of claim 1 on a skin surface, said process comprising removing a solvent in an hydroalcoholic solution or suspension containing a half (C.sub.1-C.sub.4) alkyl ester of a PVM/MA copolymer, a water miscible alcohol and a product of interest, wherein the amount of water is lower than the necessary amount of water to form the nanoparticles. 20. The composition according to claim 8, wherein said composition is in the form of a dry powder. 21. The nanoparticle according to claim 1, wherein said nanoparticle has long-term stability in aqueous media for at least three months. 22. The nanoparticle according to claim 1, wherein said nanoparticle does not include cross-linking agents.

Details for Patent 9,351,940

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Ferring Pharmaceuticals Inc.	BRAVELLE	urofollitropin	For Injection	021289	05/06/2002		2031-04-15
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2031-04-15
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	02/19/2002		2031-04-15